Wells Fargo Downgrades Thoratec (THOR) to Market Perform; Market Softness And HTWR Momentum Dampen Near-Term Outlook
Tweet Send to a FriendGet Alerts THOR Hot Sheet
Price: $31.39 -0.41%
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade THOR Now!
Wells Fargo downgraded Thoratec (NASDAQ: THOR) from Outperform to Market Perform, price target range of $27-$28 vs. $34-35.
Wells analyst says, "We believe (1) the LVAD market in the U.S. (66% of worldwide sales) was soft in Q4 2011 and this will result in a reduction in Street estimates for 2012 and beyond; and (2) THOR’s main competitor, HeartWare, appears to have regained momentum in the U.S. Preliminary results from 17 centers in our monthly LVAD survey indicate that the U.S. LVAD market and THOR’s HeartMate II declined year over year in Q4 2011 by 7% and 5%, respectively. This compares to our current U.S. LVAD market and HeartMate II estimates of +18% and +12%, respectively. To meet our THOR Q4 revenue estimate of $106MM (vs. consensus of $111MM), we estimate centers outside of our survey need implant volume to grow 8%."
"...The sample size of our survey is admittedly small, but we think it points to a weak market overall. In addition, there was a sequential increase in Heartware (Nasdaq: HTWR) implants in December which was broad based across the centers in our survey...
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $30.13 yesterday, with a 52 week range of $22.33-$38.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Wells analyst says, "We believe (1) the LVAD market in the U.S. (66% of worldwide sales) was soft in Q4 2011 and this will result in a reduction in Street estimates for 2012 and beyond; and (2) THOR’s main competitor, HeartWare, appears to have regained momentum in the U.S. Preliminary results from 17 centers in our monthly LVAD survey indicate that the U.S. LVAD market and THOR’s HeartMate II declined year over year in Q4 2011 by 7% and 5%, respectively. This compares to our current U.S. LVAD market and HeartMate II estimates of +18% and +12%, respectively. To meet our THOR Q4 revenue estimate of $106MM (vs. consensus of $111MM), we estimate centers outside of our survey need implant volume to grow 8%."
"...The sample size of our survey is admittedly small, but we think it points to a weak market overall. In addition, there was a sequential increase in Heartware (Nasdaq: HTWR) implants in December which was broad based across the centers in our survey...
For an analyst ratings summary and ratings history on Thoratec click here. For more ratings news on Thoratec click here.
Shares of Thoratec closed at $30.13 yesterday, with a 52 week range of $22.33-$38.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
- Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
